$1.52 Million is the total value of Cormorant Asset Management, LP's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 43.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Sell | PROMETHEUS BIOSCIENCES INC | $177,615 | -22.7% | 1,655,000 | -20.8% | 11.70% | -24.0% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $89,706 | +10.0% | 1,360,000 | -13.8% | 5.91% | +8.3% |
| Sell | ARCELLX INC | $49,296 | -23.3% | 1,600,000 | -22.9% | 3.25% | -24.5% | |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $40,096 | -34.6% | 2,612,115 | -5.4% | 2.64% | -35.6% |
| AVTE | Sell | AEROVATE THERAPEUTICS INC | $31,499 | -45.1% | 1,561,696 | -20.2% | 2.07% | -45.9% |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $21,624 | -32.7% | 850,000 | -22.7% | 1.42% | -33.8% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $18,504 | -26.2% | 300,000 | -7.7% | 1.22% | -27.3% |
| TARS | Sell | TARSUS PHARMACEUTICALS INC | $17,867 | -29.8% | 1,421,422 | -18.1% | 1.18% | -30.9% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $15,161 | -41.5% | 110,000 | -45.0% | 1.00% | -42.4% |
| CABA | Sell | CABALETTA BIO INC | $15,066 | -17.4% | 1,821,739 | -7.6% | 0.99% | -18.7% |
| KRTX | Sell | KARUNA THERAPEUTICS INC | $14,531 | -32.8% | 80,000 | -27.3% | 0.96% | -33.8% |
| Sell | ASTRIA THERAPEUTICS INC | $13,300 | -45.9% | 1,000,000 | -39.4% | 0.88% | -46.7% | |
| PCVX | Sell | VAXCYTE INC | $10,307 | -33.9% | 275,000 | -15.4% | 0.68% | -34.9% |
| COGT | Sell | COGENT BIOSCIENCES INC | $7,553 | -27.4% | 700,000 | -22.2% | 0.50% | -28.6% |
| BCAB | Sell | BIOATLA INC | $3,165 | -89.6% | 1,181,115 | -67.9% | 0.21% | -89.8% |
| PSTX | Sell | POSEIDA THERAPEUTICS INC | $3,080 | -49.5% | 1,000,000 | -13.0% | 0.20% | -50.2% |
| Sell | PYXIS ONCOLOGY INC | $1,093 | +22.0% | 272,537 | -59.3% | 0.07% | +20.0% | |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCspon ads | $0 | – | -256,649 | -100.0% | -0.01% | – |
| YMAB | Exit | Y-MABS THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.05% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.32% | – |
| ACET | Exit | ADICET BIO INC | $0 | – | -600,000 | -100.0% | -0.36% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -50,000 | -100.0% | -0.41% | – |
| ALT | Exit | ALTIMMUNE INCcall | $0 | – | -400,000 | -100.0% | -0.44% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -400,000 | -100.0% | -0.48% | – |
| ARQT | Exit | ARCUTIS BIOTHERAPEUTICS INC | $0 | – | -650,000 | -100.0% | -0.64% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -400,000 | -100.0% | -1.21% | – |
| Exit | AMYLYX PHARMACEUTICALS INC | $0 | – | -550,000 | -100.0% | -1.36% | – | |
| Exit | VENTYX BIOSCIENCES INC | $0 | – | -1,080,643 | -100.0% | -2.37% | – | |
| ALT | Exit | ALTIMMUNE INC | $0 | – | -2,600,000 | -100.0% | -2.86% | – |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -1,895,066 | -100.0% | -3.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.